Extended versus limited pelvic lymphadenectomy during radical prostatectomy for intermediate- and high-risk prostate cancer: Early outcomes from a randomized controlled phase III study.

被引：10
|
作者：
Lestingi, Jean Felipe Prodocimo
Guglielmetti, Giuliano
Pontes, Jose, Jr.
Mitre, Anuar Ibrahim
Sarkis, Alvaro
Bastos, Diogo Assed
Riechelmann, Rachel
Mattedi, Romulo Loss
Cordeiro, Mauricio
Coelho, Rafael
Srougi, Miguel
Nahas, William Carlos
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5018
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study
    Susumu, Nobuyuki
    Sagae, Satoru
    Udagawa, Yasuhiro
    Niwa, Kenji
    Kuramoto, Hiroyuki
    Satoh, Shinji
    Kudo, Ryuichi
    GYNECOLOGIC ONCOLOGY, 2008, 108 (01) : 226 - 233
  • [42] PROSPECTIVE RANDOMIZED CLINICAL PHASE-III TRIAL OF LIMITED VS EXTENDED PELVIC LYMPHADENECTOMY IN INTERMEDIATE AND HIGH RISK PROSTATE CANCER (PCA) - FIRST DESCRIPTIVE RESULTS (SEAL, AUO AP 55/09)
    Schwerfeld-Bohr, Julia
    Krege, Susanne
    Graefen, Markus
    Witt, Joern
    Heidenreich, Axel
    JOURNAL OF UROLOGY, 2014, 191 (04): : E513 - E513
  • [43] Pelvic SABR with HDR boost in intermediate- and high-risk prostate cancer (SPARE): Favorable early toxicity and quality-of-life outcomes.
    Musunuru, Hima Bindu
    Deabre, Andrea
    Davidson, Melanie
    Ravi, Ananth
    Helou, Joelle Antoine
    Ho, Ling
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [44] Outcomes of Hypofractionated SBRT Boost for Intermediate- and High-Risk Prostate Cancer: A Single Institutional Prospective Study
    Anwar, M.
    Weinberg, V.
    Hsu, I. J.
    Roach, M.
    Gottschalk, A. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S105 - S106
  • [45] Correction to: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer
    Lui Shiong Lee
    Adelene Y. L. Sim
    Chee Wee Ong
    Xinyan Yang
    Cedric C. Y. Ng
    Wei Liu
    Vikneswari Rajasegaran
    Abner M. S. Lim
    Edwin Jonathan Aslim
    Nye-Thane Ngo
    Li-Yan Khor
    Ravindran Kanesvaran
    John Carson Jr Allen
    Kae Jack Tay
    John Shyi Peng Yuen
    Tsung Wen Chong
    Sun Sien Henry Ho
    Bin Tean Teh
    Melvin L. K. Chua
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 803 - 803
  • [46] FOCAL ABLATION VERSUS RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: INTERIM ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL
    Baco, Eduard
    Berg, Rolf Eigil
    Eggesbo, Heidi B.
    Rud, Erik
    JOURNAL OF UROLOGY, 2021, 206 : E815 - E815
  • [47] IMPACT OF EXTENDED VS LIMITED PELVIC LYMPH NODE DISSECTION ON BIOCHEMICAL RECURRENCE IN INTERMEDIATE AND HIGH-RISK PROSTATE CANCER
    Hinojosa-Gonzalez, David E.
    Nolazco, Jose I.
    Saffati, Gal
    Kronstedt, Shane
    Jones, Jeffrey A.
    Kadmon, Dov
    Badal, Justin
    Slawin, Jeremy R.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E955 - E956
  • [48] Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers
    Sundi, Debasish
    Tosoian, Jeffrey J.
    Nyame, Yaw A.
    Alam, Ridwan
    Achim, Mary
    Reichard, Chad A.
    Li, Jianbo
    Wilkins, Lamont
    Schwen, Zeyad
    Han, Misop
    Davis, John W.
    Klein, Eric A.
    Schaeffer, Edward M.
    Stephenson, Andrew J.
    Ross, Ashley E.
    Chapin, Brian F.
    CANCER, 2019, 125 (03) : 391 - 397
  • [49] Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials
    Wei Guo
    Yun-Chuan Sun
    Jian-Qiang Bi
    Xin-Ying He
    Li Xiao
    BMC Cancer, 19
  • [50] Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials
    Guo, Wei
    Sun, Yun-Chuan
    Bi, Jian-Qiang
    He, Xin-Ying
    Xiao, Li
    BMC CANCER, 2019, 19 (01)
12345